

## **Publication**

Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

## JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

**ID** 4514959

**Author(s)** Anzengruber, Florian; Ghosh, Adhideb; Maul, Julia-Tatjana; Drach, Mathias; Navarini, Alexander A

Author(s) at UniBasel Navarini, Alexander;

Year 2018

**Title** Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis

**Journal** Psoriasis

Volume 8

Pages / Article-Number 7-11

Keywords Cw6; HLA-Cw6; genetic variations; human leukocyte antigen; ustekinumab

Several studies have suggested that an HLA-Cw6+ allele can predict an improved outcome of treatment in psoriasis patients. The aim of the study was to assess whether the published association between HLA-Cw6 allele carriers and response to ustekinumab has the potential to impact treatment decisions.; Differences in Psoriasis Activity and Severity Index 50, 75, and 90; Nail Psoriasis Severity Index; and Dermatology Life Quality Index at 16 weeks were evaluated between HLA-Cw6 allele carriers vs. non-carriers. Thirty patients with moderate-to-severe psoriasis under treatment with ustekinumab were included in our study.; There was no difference between the two groups with respect to Psoriasis Activity and Severity Index 50, 75, and 90 or in terms of change in Nail Psoriasis Severity Index or Dermatology Life Quality Index.; In our retrospectively analyzed cohort, we could not detect the previously reported better response in HLA-Cw6+ vs. HLA-Cw6- patients.

Publisher DOVE MEDICAL PRESS LTD

**ISSN/ISBN** 2230-326X

edoc-URL https://edoc.unibas.ch/72196/

Full Text on edoc No;

Digital Object Identifier DOI 10.2147/PTT.S161437

PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/29721444

ISI-Number WOS:000428404300001

Document type (ISI) Journal Article